• In late June 2026, Incyte announced that the European Medicines Agency’s CHMP issued a positive opinion recommending approval of Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis in Europe, based on Phase 3 data showing meaningful symptom improvement and a favorable safety profile in patients inadequately served by existing topical treatments.
• This regulatory progress for Opzelura, alongside detailed clinical results highlighting sustained efficacy and quality-of-life benefits, underscores how Incyte is working to expand its dermatology franchise and broaden the drug’s commercial reach beyond its current indications and geographies.
• We’ll now examine how the CHMP’s positive opinion on Opzelura for moderate atopic dermatitis could influence Incyte’s broader investment narrative.

Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

Incyte Investment Narrative Recap

To own Incyte, you need to believe the company can use drugs like Opzelura to gradually lessen its dependence on Jakafi while managing rising R&D and pricing pressures. The CHMP’s positive opinion on Opzelura in moderate atopic dermatitis looks like a supportive near term catalyst for Incyte’s push in dermatology, while the biggest ongoing risk remains how effectively it replaces Jakafi revenue ahead of future competition. The recent Russell index removals do not materially change that core debate.

The most relevant recent update here is the CHMP’s June 26 opinion on Opzelura, which directly ties to this potential new European indication. It builds on prior TRuE AD data releases and highlights Incyte’s effort to expand Opzelura’s use cases and geography, a key part of the company’s broader catalyst set that also includes new oncology indications like Zynyz and tafasitamab, and newer assets such as the mutant CALR antibody program.

Yet beneath Opzelura’s momentum, investors should still be aware of how exposed Incyte is if Jakafi’s patent protection weakens and...

Incyte's narrative projects $6.0 billion revenue and $1.4 billion earnings by 2029. This requires 4.0% yearly revenue growth with earnings remaining flat from $1.4 billion today.

Uncover how Incyte's forecasts yield a $108.50 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some analysts are far more optimistic, assuming revenue could reach about US$8.5 billion and earnings US$2.2 billion by 2029, while also betting that geographic Opzelura growth will offset Jakafi risk more smoothly than the baseline view suggests, reminding you that opinions on Incyte’s upside can differ widely and may shift again after this latest Opzelura news.

Explore 4 other fair value estimates on Incyte - why the stock might be worth 30% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Incyte research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Incyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Incyte's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.